AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its FDA-approved therapy.

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

The acquisition gives AstraZeneca full global control of the therapy’s development, manufacturing and commercialisation.

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Since their launch in 2017, chimeric antigen receptor T-cell therapies ...

CAR T-cell therapy demand is rising, prompting institutions to expand access and reduce care barriers, exemplified by Vanderbilt-Ingram Cancer Center's outpatient center. Dr. Oluwole emphasizes ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...